Ataxin 10 抗体
Quick Overview for Ataxin 10 抗体 (ABIN2856106)
抗原
See all Ataxin 10 (ATXN10) 抗体适用
宿主
克隆类型
标记
应用范围
-
-
交叉反应
- 人
-
产品特性
-
Rabbit Polyclonal antibody to ATXN10 (ataxin 10)
ATXN10 antibody -
纯化方法
- Purified by antigen-affinity chromatography.
-
免疫原
- Recombinant protein encompassing a sequence within the center region of human ATXN10. The exact sequence is proprietary.
-
亚型
- IgG
-
-
anti-Ataxin 10 (ATXN10) (AA 116-302) antibody
ATXN10 适用: 人 WB, IHC, IP, FACS, ICC 宿主: 兔 Polyclonal unconjugated
anti-Ataxin 10 (ATXN10) (AA 346-475) antibodyATXN10 适用: 人 WB, IF 宿主: 兔 Polyclonal unconjugated
anti-Ataxin 10 (ATXN10) (AA 1-109) antibodyATXN10 适用: 人 WB, ELISA 宿主: 小鼠 Polyclonal unconjugated
anti-Ataxin 10 (ATXN10) (AA 1-475) antibodyATXN10 适用: 人 WB 宿主: 小鼠 Polyclonal unconjugated
anti-Ataxin 10 (ATXN10) (N-Term) antibodyATXN10 适用: 人, 小鼠, 大鼠 WB, ELISA 宿主: 兔 Polyclonal unconjugated
anti-Ataxin 10 (ATXN10) (C-Term) antibodyATXN10 适用: 人, 小鼠, 猴, 犬, 马, Pig WB 宿主: 兔 Polyclonal unconjugated
anti-Ataxin 10 (ATXN10) (N-Term) antibodyATXN10 适用: 人 WB 宿主: 兔 Polyclonal unconjugated
-
-
应用备注
- WB: 1:500-1:3000. IHC-P: 1:100-1:1000. Optimal dilutions/concentrations should be determined by the researcher. Not tested in other applications.
-
说明
-
Positive Control: 293T , A431 , HeLa , HepG2 , U87-MG , SK-N-SH , IMR32 , SK-N-AS
-
限制
- 仅限研究用
-
-
-
状态
- Liquid
-
浓度
- 0.78 mg/mL
-
缓冲液
- 1XPBS ( pH 7), 1 % BSA, 20 % Glycerol, 0.01 % Thimerosal
-
储存液
- Thimerosal (Merthiolate)
-
注意事项
- This product contains Thimerosal (Merthiolate): a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.
-
储存条件
- 4 °C,-20 °C
-
储存方法
- Store as concentrated solution. Centrifuge briefly prior to opening vial. For short-term storage (1-2 weeks), store at 4°C. For long-term storage, aliquot and store at -20°C or below. Avoid multiple freeze-thaw cycles.
-
-
- Ataxin 10 (ATXN10)
-
别名
- ataxin 10
-
背景
-
The autosomal dominant cerebellar ataxias (ADCAs) are a clinically and genetically heterogeneous group of disorders characterized by ataxia, dysarthria, dysmetria, and intention tremor. All ADCAs involve some degree of cerebellar dysfunction and a varying degree of signs from other components of the nervous system. A commonly accepted clinical classification (Harding, 1993) divides ADCAs into 3 different groups based on the presence or absence of associated symptoms such as brainstem signs or retinopathy. The presence of pyramidal and extrapyramidal symptoms and ophthalmoplegia makes the diagnosis of ADCA I, the presence of retinopathy points to ADCA II, and the absence of associated signs to ADCA III. Genetic linkage and molecular analyses revealed that ADCAs are genetically heterogeneous even within the various subtypes.[supplied by OMIM]
-
分子量
- 53 kDa
-
基因ID
- 25814
-
UniProt
- Q9UBB4
抗原
-
